$CATX

Lantheus Alpha Therapy, LLC sold $131K of CATX

Lantheus Alpha Therapy, LLC sold 42,129 shares of Perspective Therapeutics, Inc. (CATX) at $3.11 ($0.13M total) on 2026-09-02. Filed jointly with Lantheus Holdings, Inc. (10% owner).

Original reporting
SEC EDGAR · Lantheus Alpha Therapy, LLC, Lantheus Holdings, Inc.
Published Sep 4, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CATX
Neutral
high confidence
Mentioned
$CATX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CATXNeutralLow
01

Why it matters

The disclosed sale is a routine insider transaction with limited market impact.

02

Market read

Minor insider sell; unlikely to affect stock price materially.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 4/10Novelty 4/10Timing: filed Sep 4 2026

Background

SEC Form 4 filing by Lantheus Alpha Therapy, LLC reporting an insider transaction for Perspective Therapeutics.

Company-level read

Ticker impact

$CATXNeutralHigh confidence
Context

Form 4 disclosed a 10% owner sold 42,129 shares for $131,219, reducing holdings to 11.5M shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is small relative to total shares and market cap; insider still holds >10%.

Market effects

None

None

None

Counterpoint

Insider sale could signal concerns, but size is trivial.

Key entities

  • Perspective Therapeutics, Inc.

    Biopharma company whose insider sold shares.

  • Lantheus Alpha Therapy, LLC

    10% owner reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CATXMed

Perspective Therapeutics, Inc. (CATX): Results of Operations and Financial Condition

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results • Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 s